Literature DB >> 16997154

Symptoms and diagnosis of gastric cancer at early curable stage.

Anthony Axon1.   

Abstract

Five-year survival of gastric cancer is 10% in Western countries compared with over 50% in Japan. This is because the disease is not identified in the West until later in its evolution. T1 cancer has an excellent prognosis, but most of the patients either have no symptoms or complain of long-standing, non-specific dyspepsia; alarm symptoms, when identified, usually indicate that the cancer is already inoperable. Early gastric cancer is infrequently diagnosed in the West because the low prevalence of gastric cancer means that endoscopists do not search with the same diligence as they do in Japan. A further barrier is the widespread prescription of proton pump inhibitors that heal malignant ulcers and diminish symptoms, thus rendering them more difficult to identify clinically and endoscopically. An improvement in diagnosis may be achieved by newer endoscopy technology which enables cancers to be identified more easily, or by an inexpensive screening test to select patients with extensive gastric atrophy, thereby identifying those at risk who can then be screened endoscopically.

Entities:  

Mesh:

Year:  2006        PMID: 16997154     DOI: 10.1016/j.bpg.2006.03.015

Source DB:  PubMed          Journal:  Best Pract Res Clin Gastroenterol        ISSN: 1521-6918            Impact factor:   3.043


  27 in total

1.  Endoscopic mucosal resection and endoscopic submucosal dissection as treatments for early gastrointestinal cancers in Western countries.

Authors:  Sergio Coda; Sun-Young Lee; Takuji Gotoda
Journal:  Gut Liver       Date:  2007-06-30       Impact factor: 4.519

2.  Endoscopic quality indicators for esophagogastroduodenoscopy in gastric cancer screening.

Authors:  Chan Hyuk Park; Bun Kim; Hyunsoo Chung; Hyuk Lee; Jun Chul Park; Sung Kwan Shin; Sang Kil Lee; Yong Chan Lee
Journal:  Dig Dis Sci       Date:  2014-07-26       Impact factor: 3.199

3.  Circulating SH2B1 is associated with an increased risk of gastric cancer.

Authors:  Bo Liu; Feng Li; Hong-Peng Zhao; Jing-Bo Chen; Yu-Peng Li; Hai-Hua Yu
Journal:  Oncol Lett       Date:  2018-03-07       Impact factor: 2.967

Review 4.  Utility of subtyping intestinal metaplasia as marker of gastric cancer risk. A review of the evidence.

Authors:  Carlos A González; José M Sanz-Anquela; Javier P Gisbert; Pelayo Correa
Journal:  Int J Cancer       Date:  2013-02-05       Impact factor: 7.396

5.  Upper gastrointestinal cancer in its early stages is predominantly asymptomatic.

Authors:  James W Berrill; Jeff K Turner; Jo J Hurley; Gillian Swift; Sunil Dolwani; John T Green
Journal:  Frontline Gastroenterol       Date:  2011-09-10

6.  British Society of Gastroenterology guidelines on the diagnosis and management of patients at risk of gastric adenocarcinoma.

Authors:  Matthew Banks; David Graham; Marnix Jansen; Takuji Gotoda; Sergio Coda; Massimiliano di Pietro; Noriya Uedo; Pradeep Bhandari; D Mark Pritchard; Ernst J Kuipers; Manuel Rodriguez-Justo; Marco R Novelli; Krish Ragunath; Neil Shepherd; Mario Dinis-Ribeiro
Journal:  Gut       Date:  2019-07-05       Impact factor: 23.059

7.  Missed diagnosis of early gastric cancer or high-grade intraepithelial neoplasia.

Authors:  Wei Ren; Jin Yu; Zhi-Mei Zhang; Yuan-Kun Song; Yi-Hui Li; Lei Wang
Journal:  World J Gastroenterol       Date:  2013-04-07       Impact factor: 5.742

8.  Gastric cancer presenting with solitary gigantic pelvic metastasis.

Authors:  Qi Zheng; Kejun Nan; Yu Yao
Journal:  J Biomed Res       Date:  2012-04-15

9.  Expression of MT2 receptor in patients with gastric adenocarcinoma and its relationship with clinicopathological features.

Authors:  Nafiseh Nasri Nasrabadi; Ramin Ataee; Saeid Abediankenari; Mohammad Shokrzadeh; Mojtaba Najafi; Seyed Vahid Hoseini; Hamed Haghi Amin Jan
Journal:  J Gastrointest Cancer       Date:  2014-03

Review 10.  Role of symptoms in diagnosis and outcome of gastric cancer.

Authors:  Giovanni Maconi; Gianpiero Manes; Gabriele-Bianchi Porro
Journal:  World J Gastroenterol       Date:  2008-02-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.